Equities researchers at HC Wainwright issued their FY2029 earnings estimates for shares of Daré Bioscience in a research note ...

Stock analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for CalciMedica in a report issued on Tuesday, April 1st. HC Wainwright analyst J. Pantginis expects that the company ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

H.C. Wainwright analyst Douglas Tsao views the agreement of joint stipulation between Arcutis Biotherapeutics (ARQT) and Padagis to the ongoing ...

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Zura Bio (ZURA) to $3 from $5 and keeps a Buy rating on the shares ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Surf Air Mobility Inc. (NYSE: SRFM) (the "Company"), a leading regional air mobility platform, closed on the previously announced purchase and sale of 2,000,000 shares of common stock (or pre-funded ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.